You are here
FDA Notifies Health Care Professionals About Prescribing Errors Involving Zyprexa and Zyrtec
February 9, 2005
Eli Lilly and FDA notified healthcare professionals reports of medication dispensing or prescribing errors between the atypical antipsychotic ZyPREXA (olanzapine), indicated for the short-term and maintenance treatment of schizophrenia and for the short-term treatment of acute mixed or manic episodes associated with Bipolar I Disorder, and the antihistamine ZYRTEC (cetirizine HCI) marketed by Pfizer, indicated for the treatment of allergic rhinitis or chronic urticaria. These reports include instances where Zyprexa was incorrectly dispensed for Zyrtec and vice versa, leading to unnecessary adverse events or potential relapse in patients suffering from schizophrenia or bipolar disorder.
To review the letter from Eli Lilly, click here.
Source: The Food and Drug Administration
Disrupting Gut Microbiome Could Be Key
Drug Boosts Levels of Natural Endocannabinoids
Judicious Use of Antibiotics May Not Be Enough To Defeat Bacteria That Carry On By Going Into a Dormant State
KRAS Oncogene Is a Problematic Target So Researchers Are Trying Workdarounds
Understanding Neural Ensembles in Infralimbic Cortex May Lead To Improved Addiction Treatment
Nag With Texting and a ‘Winners Circle’
How Serotonin and Fluoxetine Affect Microbiota Residing in the Gut
Modified gold-based molecules show promise as effective, targeted treatment
Vitamin E Found in Samples Around the Country